Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Biliary Tract Neoplasms × larotrectinib × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Sarcoma 1 Head & Neck 1 Gastrointestinal 1 Dermatologic 1 Breast 1

Conditions

Thyroid Neoplasms 1 Sarcoma 1 Salivary Gland Neoplasms 1 Neoplasms 1 Melanoma 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

tremelimumab 1 pembrolizumab 1 larotrectinib 1 durvalumab 1 AZD 6244 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02576431 2025-11-12

NAVIGATE

Bayer

Phase 2 Completed

215 enrolled 3 FDA

BreastDermatologicGastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Salivary Gland Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡